WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN

IgA nephropathy is a B-cell mediated disease associated with progressive loss of kidney function and a high lifetime risk of kidney failure. Current treatments fail to stop the decline in kidney function, highlighting the need for effective disease-modifying therapies. Atacicept is a fully humanized TACI-Fc fusion protein that binds and inhibits B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), the key cytokines that drive B-cell activation central to the pathogenesis of IgA nephropathy.